Amonafide dihydrochloride | 150091-68-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: Amonafide dihydrochloride
• 英文别名: 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione;dihydrochloride
• CAS: 150091-68-2
• 化学式: C16H19Cl2N3O2
• 分子量: 356.2
• InChiKey: AEMLYYQEBPJIEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.42
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] NAPHTHALIMIDE SYNTHESIS INCLUDING AMONAFIDE SYNTHESIS AND PHARMACEUTICAL PREPARATIONS THEREOF<br/>[FR] SYNTHESE DE NAPHTALIMIDES, Y COMPRIS D'AMONAFIDES, ET PREPARATIONS PHARMACEUTIQUES LES CONTENANT
  申请人：CHEMGENEX THERAPEUTICS INC

  公开号：WO2004004716A1

  公开（公告）日：2004-01-15

  The present invention concerns novel methods for the synthesis of naphthalimides and mitonafide analogs, as well as salts thereof. Also included are novel compositions, including naphthalimides and naphthalimide salts, analogs thereof, as well as stable liquid dosage forms thereof.

  本发明涉及一种合成萘酰亚胺和米托那菲类似物及其盐的新方法。还包括新的组合物，包括萘酰亚胺和萘酰亚胺盐、类似物及其稳定的液态剂型。
• Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof
  申请人：ChemGenex Therapeutics, Inc.

  公开号：US20040082788A1

  公开（公告）日：2004-04-29

  The present invention concerns novel methods for the synthesis of naphthalimides and mitonafide analogs, as well as salts thereof. Also included are novel compositions, including naphthalimides and naphthalimide salts, analogs thereof, as well as stable liquid dosage forms thereof.

  本发明涉及一种合成萘酰亚胺和mitonafide类似物及其盐的新方法。还包括新的组合物，包括萘酰亚胺和萘酰亚胺盐，类似物以及其稳定的液态剂量形式。
• Amonafide salts and compositions comprising same
  申请人：ChemGenex Pharmaceuticals, Inc.

  公开号：EP2305257A1

  公开（公告）日：2011-04-06

  The present invention concerns novel methods for the synthesis of napthalimides and mitonafide analogs, as well as salts thereof. Also included are novel compositions, including napthalimides and napthalimide salts, analogs thereof, as well as stable liquid dosage forms thereof.

  本发明涉及合成萘啶酰亚胺和螨酰亚胺类似物及其盐类的新方法。本发明还包括新型组合物，包括萘啶酰亚胺和萘啶酰亚胺盐、其类似物及其稳定的液体剂型。
• アモナフィドを含むナフタルイミドの製造およびその医薬製剤
  申请人：ケムジェネックス・ファーマシューティカルズ・リミテッド

  公开号：JP2005533088A

  公开（公告）日：2005-11-04

  本発明は、ナフタルイミド、およびミトナフィドアナログ、並びにそれらの塩の新規な製造方法を提供する。本発明はまた、ナフタルイミド、およびナフタルイミド塩、それらのアナログを含有する新規な組成物、並びにそれらの安定な液体投与形態をも提供する。

  本发明提供了生产萘啶酰亚胺和螨酰亚胺类似物及其盐类的新方法。本发明还提供了含有萘啶酰亚胺和萘啶酰亚胺盐、它们的类似物的新型组合物及其稳定的液体剂型。
• Engineered platelets for targeted delivery of a therapeutic agent
  申请人：JPV01 LTD.

  公开号：US11518796B2

  公开（公告）日：2022-12-06

  The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogemc platelets.

  本发明提供了具有所需靶向特异性嵌合血小板受体（CPR）的工程血小板。此外，人造血小板可包含货物，货物可在血小板活化时释放。此外，血小板可由巨核细胞体外生成，以产生非血栓性血小板。